MedPath

Effect of Dexmedetomidine on the Prevention of Emergence Agitation in Children Undergoing Day Surgery

Registration Number
NCT03262090
Lead Sponsor
Guangzhou Women and Children's Medical Center
Brief Summary

Emergence agitation/delirium (EA/ED) is a common complication in pediatric surgery patients, which increases the risk of developing postoperative airway obstruction and respiratory depression. In infants, there is a high incidence of emergence agitation (EA) after desoflurane anesthesia. The aim of the present preliminary study was to determine the safety and efficacy of of intraoperative infusion of dexmedetomidine (DEX) that would prevent postoperative EA and ED in children undergoing day surgery with desoflurane anesthesia

Detailed Description

subjects who underwent day surgery were stratified into two age groups as follows: low to 3 years group, and 3-12 years group. Then they were randomly assigned to receive one of six doses of intravenous dexmedetomidine: 0, 0.2, 0.4, 0.6, 0.8 ,1.0ug/kg before skin incision.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
389
Inclusion Criteria
  1. patients who undergo elective unilateral inguinal hernia or hydrocele testis day surgery
  2. Patients who are American Society of Anesthesiologists classification I and II
  3. Patients who are 4 months through 15 years of age
Exclusion Criteria
  1. children with history of respiratory tract infection 1 week preoperatively. 2. patients with preoperative liver and/or kidney dysfunction, or with mental abnormalities.

  2. patients with any congenital malformation or acquired disease that could increase the risks of anesthesia and the dose of anesthetics (such as, but not limited to, congenital heart disease, hydronephrosis, nutrition dysplasia). 4. patients with long-term use of sedative or analgesic drugs.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
0.4ug/kg dexmedetomidine0.4ug/kg dexmedetomidineSubjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
0.6ug/kg dexmedetomidine0.6ug/kg dexmedetomidineSubjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
0.8ug/kg dexmedetomidine0.8ug/kg dexmedetomidineSubjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
0.2ug/kg dexmedetomidine0.2ug/kg dexmedetomidineSubjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
1.0ug/kg dexmedetomidine1.0ug/kg dexmedetomidineSubjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
Primary Outcome Measures
NameTimeMethod
incidence of emergence agitation at different time interval after emergenceat 5min, 10min, 20min, 30min, 40min, 50min, 60min, 2h after emergence

emergence agitation was evaluated by five-point scale

Secondary Outcome Measures
NameTimeMethod
sedation scales at different time interval after emergenceat 5min, 10min, 20min, 30min, 40min, 50min, 60min, 2h after emergence

sedation was evaluated by MOAA/S scores

incidence of emergence delirium at different time interval after emergenceat 5min, 10min, 20min, 30min, 40min, 50min, 60min, 2h after emergence

emergence delirium was evaluated by five-point scale

pain scale at different time interval after emergenceat 5min, 10min, 20min, 30min, 40min, 50min, 60min, 2h after emergence

pain scale was evaluated by FLACC

Trial Locations

Locations (1)

Guangzhou Women and Children Medical Center

🇨🇳

Guangzhou, Guangdong, China

Guangzhou Women and Children Medical Center
🇨🇳Guangzhou, Guangdong, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.